Effect of levodopa and clioquinol on antioxidant capacity in Parkinson's disease rhesus monkeys
Like LI,Liangqin SHI,Heng LIU,Qihui LUO,Chao HUANG,Wentao LIU,Xiaolin CHEN,Zhengli CHEN
DOI: https://doi.org/10.3785/j.issn.1008-9209.2016.05.251
2017-01-01
Abstract:Parkinson's disease (PD), characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta of the brain,is the second most common neurodegenerative disease. It includes the major motor symptoms of akinesia, rigidity and tremor. Main mechanisms of the neuronal degeneration of PD include free radicals and oxidative stress, mitochondrial dysfunction, excitotoxicity, calcium cytotoxicity, trophic factor deficiency, inflammatory processes, genetic factors, environmental impact factors, toxic action of nitric oxide, and apoptosis, all of which may interact with and amplify each other in a vicious cycleof toxicity, leading to neuronal dysfunction, atrophy, and finally cell death. Eight healthy young rhesus monkeys were respectively daily injected a small dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by intramuscular injection, then divided into a levodopa group (three rhesus monkeys), a clioquinol group (three rhesus monkeys) and a control group (two rhesus monkeys) randomly, and given 15 mg/kg levodopa + carbidopa, 15 mg/kg clioquinol and equal physiological saline by oral for 4 weeks respectively. The behavioral manifestations of all monkeys were evaluated, and their serum biochemical indices were measured before and after different drug treatments, including superoxide dismutase (SOD), glutathione peroxidase (GPX), glutathione S-transferase (GST), glutathione (GSH) and malondialdehyde (MDA). With the continued injection of MPTP, the monkeys reached a state of stable parkinsonism, which was first obtained on the 62 days of treatment. Since then, no significant variation was observed. In addition, vocalization reduction was the first symptom, but it was indistinct; furthermore, we found that the monkeys became increasingly bradykinetic, and finally presented with tremors, which were stronger and earlier at the arms than at the legs. Other early phenotypes and long-lasting symptoms included a decrease in home cage activity and arm movement, and an increase of muscular rigidity and freeze. The behavior scores of the levodopa group and clioquinol group decreased after the treatment, and the difference was statistically significant, but the control group showed no significant differences. The activities of SOD, GPX, GST and the GSH content were all increased, while MDA concentration decreased in the levodopa group and clioquinol group; the above indexes in the levodopa group had statistical significance (P<0.05), as well as the levels of GST and GSH in the clioquinol group (P<0.05). Compared with the control group, the activities of SOD and GST increased significantly (P<0.01), while the GPX activity and the MDA concentration decreased significantly (P<0.05) in the levodopa group; the SOD activity and the GSH content increased significantly (P<0.05), but the GPX activity decreased significantly (P<0.01) in the clioquinol group. The above results show that levodopa and clioquinol can increase the blood antioxidant enzyme activity and decrease the lipid peroxide content, and then enhance the body's antioxidant capacity and promote the recovery of clinical behavior, thus playing a positive role in PD monkeys.